Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone
A Phase Ib/II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of JMT103 in Surgically Unsalvageable or Refractory Giant Cell Tumor of Bone
Sponsor: Shanghai JMT-Bio Inc.
A PHASE1/PHASE2 clinical study on Giant Cell Tumor of Bone, this trial is ongoing. The trial is conducted by Shanghai JMT-Bio Inc. and has accumulated 7 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Nov 2024 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jun 2022 — Nov 2022 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai JMT-Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .